606 related articles for article (PubMed ID: 33768439)
1. The Renin-Angiotensin System, Hypertension, and SARS-CoV-2 Infection: a Review.
Gathiram P; Mackraj I; Moodley J
Curr Hypertens Rep; 2021 Mar; 23(4):17. PubMed ID: 33768439
[TBL] [Abstract][Full Text] [Related]
2. Potential Implications of Angiotensin-converting Enzyme 2 Blockades on Neuroinflammation in SARS-CoV-2 Infection.
Paul D; Mohankumar SK; Thomas RS; Kheng CB; Basavan D
Curr Drug Targets; 2022; 23(4):364-372. PubMed ID: 34732115
[TBL] [Abstract][Full Text] [Related]
3. Renin-angiotensin-aldosterone system and COVID-19 infection.
Alexandre J; Cracowski JL; Richard V; Bouhanick B;
Ann Endocrinol (Paris); 2020 Jun; 81(2-3):63-67. PubMed ID: 32370986
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
Shukla AK; Banerjee M
High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
[TBL] [Abstract][Full Text] [Related]
5. Renin-angiotensin system at the interface of COVID-19 infection.
Gul R; Kim UH; Alfadda AA
Eur J Pharmacol; 2021 Jan; 890():173656. PubMed ID: 33086029
[TBL] [Abstract][Full Text] [Related]
6. Renin-angiotensin system modulators in COVID-19 patients with hypertension: friend or foe?
Shylesh C M S; V S A; S K K; P UD
Clin Exp Hypertens; 2022 Jan; 44(1):1-10. PubMed ID: 34414841
[No Abstract] [Full Text] [Related]
7. Drugs acting on renin angiotensin system and use in ill patients with COVID-19.
Alexandre J; Cracowski JL; Richard V; Bouhanick B;
Therapie; 2020; 75(4):319-325. PubMed ID: 32553503
[TBL] [Abstract][Full Text] [Related]
8. Unravelling the Mechanistic Role of ACE2 and TMPRSS2 in Hypertension: A Risk Factor for COVID-19.
Govender N; Khaliq O; Moodley J; Naicker T
Curr Hypertens Rev; 2022; 18(2):130-137. PubMed ID: 36508271
[TBL] [Abstract][Full Text] [Related]
9. The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future.
Zhang J; Wang M; Ding W; Wan J
Life Sci; 2020 Sep; 257():118142. PubMed ID: 32712300
[TBL] [Abstract][Full Text] [Related]
10. Therapy with RAS inhibitors during the COVID-19 pandemic.
Spaccarotella C; Mazzitelli M; Migliarino S; Curcio A; De Rosa S; Torti C; Indolfi C
J Cardiovasc Med (Hagerstown); 2021 May; 22(5):329-334. PubMed ID: 33795584
[TBL] [Abstract][Full Text] [Related]
11. New Viral Diseases and New Possible Remedies by Means of the Pharmacology of the Renin-Angiotensin System.
Sansoè G; Aragno M
J Renin Angiotensin Aldosterone Syst; 2023; 2023():3362391. PubMed ID: 37476705
[TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety.
Akhtar S; Benter IF; Danjuma MI; Doi SAR; Hasan SS; Habib AM
J Drug Target; 2020; 28(7-8):683-699. PubMed ID: 32700580
[TBL] [Abstract][Full Text] [Related]
13. Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury.
Sarzani R; Giulietti F; Di Pentima C; Giordano P; Spannella F
Am J Physiol Lung Cell Mol Physiol; 2020 Aug; 319(2):L325-L336. PubMed ID: 32639866
[TBL] [Abstract][Full Text] [Related]
14. Considerations on the use of antihypertensive blockers of the renin-angiotensin system in adults and children in the face of the COVID-19 pandemic.
Vázquez-Cornejo E
Bol Med Hosp Infant Mex; 2020; 77(5):274-281. PubMed ID: 33064690
[TBL] [Abstract][Full Text] [Related]
15. RAAS Blockade and COVID-19: Mechanistic Modeling of Mas and AT1 Receptor Occupancy as Indicators of Pro-Inflammatory and Anti-Inflammatory Balance.
Melissa Hallow K; Dave I
Clin Pharmacol Ther; 2021 Apr; 109(4):1092-1103. PubMed ID: 33506503
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 and the Angiotensin-Converting Enzyme 2 Receptor: Angiotensin-Converting Enzyme Inhibitor/Angiotensin 2 Receptor Blocker Utilization and a Shift Towards the Renin-Angiotensin-Aldosterone System Classical Pathway.
Felber R; New W; Riskin SI
Cureus; 2024 Mar; 16(3):e55563. PubMed ID: 38576704
[TBL] [Abstract][Full Text] [Related]
17. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.
Yang G; Tan Z; Zhou L; Yang M; Peng L; Liu J; Cai J; Yang R; Han J; Huang Y; He S
Hypertension; 2020 Jul; 76(1):51-58. PubMed ID: 32348166
[TBL] [Abstract][Full Text] [Related]
18. Impact of renin-angiotensin-aldosterone system inhibitors on COVID-19.
Matsuzawa Y; Kimura K; Ogawa H; Tamura K
Hypertens Res; 2022 Jul; 45(7):1147-1153. PubMed ID: 35581498
[TBL] [Abstract][Full Text] [Related]
19. Hypothesis for renin-angiotensin inhibitor mitigation of COVID-19.
Sackin H
Med Hypotheses; 2021 Jul; 152():110609. PubMed ID: 34048987
[TBL] [Abstract][Full Text] [Related]
20. Association of ACE2 receptor and ACEIs/ARBs with disease severity in COVID-19.
Sinha S; Sehgal A; Sehgal R
Drug Discov Ther; 2020; 14(4):161-170. PubMed ID: 32908071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
